|
08 Oct 2019 |
FDA Approves Octapharma’s WILATE® for Hemophilia A in Adult and Adolescent Patients
|
|
08 Oct 2019 |
Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis
|
|
08 Oct 2019 |
Intarcia Therapeutics Provides Regulatory Update - FDA Accepts Resubmitted New Drug Application For ITCA 650
|
|
08 Oct 2019 |
Stealth BioTherapeutics Presents Data on SBT-272 in Neurodegeneration
|
|
08 Oct 2019 |
Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis
|
|
08 Oct 2019 |
Axcella Provides Progress Updates for Liver Program Candidates AXA1125 and AXA1957
|
|
03 Oct 2019 |
Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor-Localized Immunotherapy
|
|
02 Oct 2019 |
Ra Pharmaceuticals Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for gMG
|
|
02 Oct 2019 |
Evolus Receives Approval for Nuceiva™ in the European Union
|
|
01 Oct 2019 |
TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic Cancer
|
|
01 Oct 2019 |
Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 for HPV16-driven Head and Neck Squamous Cell Carcinoma
|
|
29 Sep 2019 |
Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Malignant Ascites
|
|
29 Sep 2019 |
Bicycle Therapeutics Announces Presentation of Updated Data from Phase I/IIa Trial Evaluating BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress
|
|
27 Sep 2019 |
89bio Announces Dosing of First Patients in NASH Study and Issuance of Composition of Matter Patent
|
|
27 Sep 2019 |
Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Triple-Negative Breast Cancer Patients at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
|
|
27 Sep 2019 |
Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy
|
|
27 Sep 2019 |
Noveome Biotherapeutics, Inc. Initiates Phase 1 Open Label Clinical Trial Evaluating Intranasal Delivery of Lead Candidate ST266 Targeting the Optic Nerve and Brain
|
|
25 Sep 2019 |
Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease
|
|
24 Sep 2019 |
Entera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism
|
|
24 Sep 2019 |
Zealand Pharma achieves primary and all key secondary endpoints in pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia
|
|
23 Sep 2019 |
Mochida obtains marketing approval for teriparatide biosimilar in Japan
|
|
23 Sep 2019 |
Announcement of Receiving Manufacturing and Marketing Approval for Darbepoetin Alpha Biosimilars in Japan
|
|
22 Sep 2019 |
Once-weekly somapacitan demonstrates similar one-year height gains compared to daily somatropin in a phase 2 trial in children with growth hormone deficiency
|
|
20 Sep 2019 |
FDA approves Rybelsus® (semaglutide), the first GLP-1 analog treatment available in a pill for adults with type 2 diabetes
|
|
19 Sep 2019 |
Dance Biopharm Presents Phase 2 Clinical Data Highlighting Rapid Effects of Inhaled Human Insulin at European Association for the Study of Diabetes Meeting
|
